Plain-English translation of NCT02560805 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
Researchers know that people with PTSD have a higher risk of heart disease, partly because trauma keeps their nervous system in overdrive. This study tests whether or — two medications already used to treat high blood pressure — can reduce that heart risk in veterans with PTSD. The team will also test a non-invasive nerve stimulation device as an alternative treatment.
Veterans and others with PTSD face significantly higher rates of heart disease and related conditions, but we don't yet have treatments specifically designed to protect their hearts. This study aims to find a way to calm the nervous system overactivity that drives this extra cardiovascular risk.
You likely qualify if…
You likely don't qualify if…
In the first phase, all participants complete stress tests and nerve activity measurements to establish a baseline. Veterans with PTSD are then randomly assigned to take one of two medications or receive a nerve stimulation device for 8 to 14 weeks, while researchers monitor how well each treatment works. You'll have follow-up visits to measure your nervous system activity, blood pressure, and inflammation markers.
AI-generated summary from trial data · Jun 17, 2026 · Not medical advice
United States